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Abstract
Owing to the success of biologics in the treatment of rheumatoid arthritis (RA), several novel drugs
have been introduced in the therapeutic armamentarium, although not all of them have been
approved in all countries worldwide. Among the drugs are tumour necrosis factor (TNF) inhibitors
such as certolizumab pegol and golimumab (the latter of which was the first TNF blocker shown to
be effective in patients who had been unsuccessfully treated with other TNF blockers and which can
be applied only once a month), and the interleukin-6 receptor antagonist tocilizumab, which not only
opens up a completely new field of anti-inflammatory modulation of RA pathophysiology, but also
highlights the challenge of novel potential side effects. Moreover, aside from clinical studies showing
efficacy in the inhibition of osteoclast activation by the anti-RANKL (receptor activator of nuclear
factor-kappa B ligand) antibody denosumab, an improved form of steroid application known as slow-
release ‘tempus tablet’ for treatment of RA and several developments in the small-molecule area have
been addressed by clinical trials.
Introduction and context
The pathophysiology of rheumatoid arthritis (RA) pro-
vides numerous cellular, intracellular, and messenger
molecule targets, which can all be addressed by biochem-
ical as well as antibody-based biological therapeutic
agents.Ontheotherhand,noneofthecurrenttherapeutic
regimensforRAleadstoalong-term100%remissionrate,
soadditionalideasanddrugsstillneedtobecontinuously
developed and tested in clinical trials. These develop-
mentsalsoincludeimprovementofcurrentdrugsinterms
ofsafety,efficacy,andamorecomfortableapplicationfor
the individual patient. Here, some of the most important
developments in this field are presented.
Recent advances
Improvements in and around the gold standards
A milestone in the development of the therapeutic
armamentarium for RA is the modified application
form of prednisolone, which consists of prednisolone
e m b e d d e di na ni n e r th u l lt h at disintegrates after
3-5 hours of intestinal transit time and releases the
prednisolone precisely at the moment of the lowest
endogenous steroid production in the early morning
hours. When this ‘tempus tablet’ (Figure 1) was applied,
significantly reduced morning stiffness could be
achieved [1]. Similarly, as shown in a recent study, the
disease-modifying anti-rheumatic drug (DMARD) gold
standard, methotrexate, is significantly more effective
when applied subcutaneously and provides a more rapid
onset of the therapeutic effect [2]. Another strategy in the
small-molecule DMARD field is the mitogen-activated
protein (MAP) kinase inhibitor pamapimod. Although
MAP kinases are ubiquitous in inflammatory cells and
contribute significantly to the synovial activation, the
primary goal of an efficacy that was better than that of
methotrexate could not be achieved [3,4]. As shown
recently, targeting other intracellular kinases such as Jak
and Syk might be more promising. The most recently
published study, in which masitinib (a potent and
selective protein tyrosine kinase inhibitor of c-kit) was
tested in the monotherapy treatment of DMARD-
refractory RA, showed ACR20/50/70 (American College
of Rheumatology 20%/50%/70% improvement criteria)
scores of 54%, 26% and 8%, respectively, and a
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50% for approximately half of the patients [5].
Next generation tumour necrosis factor inhibitors
Approximately 10 years after the introduction of the first
tumour necrosis factor (TNF) inhibitor (infliximab),
there is still room for development and improvement
(for example, a more rapid response or achievement of
remission, or both, and an improvement of application
mode for the patient). The first biologic in this group is
the pegylated TNF inhibitor certolizumab pegol (CEZ),
which has shown a very rapid response in clinical trials
[6,7]; it has been hypothesized that the pegylation may
alsoleadtoadeeperpenetranceofthedrugintothejoints,
anideathatstillneedstobeproven.ItislicensedforRAin
the US and has just received a positive appraisal from the
European Medicines Agency and is approved for Crohn’s
disease in some other countries (such as Switzerland).
However, the overall response rates do not differ
significantly from those of the other TNF inhibitors. The
second novel TNF inhibitor, golimumab (GOM), is –
aside from adalimumab – the second fully human TNF
inhibitor and was developed with the goal of achieving a
once-a-month patient-friendly subcutaneous application
[8,9]. As this goal has been achieved in clinical trials with
an efficacy comparable to those of the other TNF
inhibitors, GOM was also recently licensed for RA in the
USandisexpectedtobelaunchedinEuropelatethisyear.
Additional novel targeted therapies
To improve the earlier approach of a biologic inhibition
of the proinflammatory and chondrocyte-activating
molecule interleukin-1 (IL-1), ACZ885, a fully human
monoclonal antibody that neutralizes the bioactivity of
human IL-1b, was generated in a small proof-of-concept
study of 32 patients [10]. A statistically significant
reduction in disease activity score was observed after
4 weeks in the 10 mg/kg group, with a rapid onset of
action in responders within the first 3 weeks. However,
the true value of IL-1 inhibition, which is significant in
fever syndromes and adult Still’s syndrome, remains to
be proven for long-term RA. With regard to the idea of
selectively reducing the activity of the bone-degrading
osteoclasts by antagonizing RANKL (receptor activator
of nuclear factor-kappa B ligand), the addition of
twice-yearly injections of denosumab to ongoing metho-
trexate treatment inhibited structural damage for up to
12 months in patients with RA, with no increase in the
rates ofadverseeventsas compared withplacebo[11,12].
The more prominent development, however, was the
licensing of the humanized anti-IL-6 receptor antagonist
tocilizumab (TOZ) for RA in some countries in Europe.
(Note: In this report, the abbreviations CEZ, GOM and
TOZareusedaccordingtoaproposedunifyingsystemfor
the nomenclature of biologics [13]). On the basis of the
results of the clinical trials, TOZ, unlike other biologics,
has been approved both for monotherapy and for first-
line biological treatment similar to first-line TNF inhibi-
tors. The data of the clinical studies [14,15] show a rapid
and persisting effect, which is further supported by the
interesting notion that, due to the very early approval in
Japan for Castleman’s disease, 5-year efficacy and safety
data are already available. However, although in Europe
several hundred patients have already been treated in the
clinical routine, novel side effects also have to be
considered in daily practice. First, it needs to be noted
that, similar to TNF, IL-6 is a pluripotent cytokine with
numerous (differing) effects in pathways modulating
inflammation and growth, but with fewer effects in the
TNF domains of atypical and opportunistic infections
and the development of lymphoma. Second, the side
effects of IL-6 inhibition are important in many other
clinically relevant settings [for example, (transient)
leukopenia and thrombopenia, the elevation of serum
lipids, and hitherto unexplained gastrointestinal
perforations].
Implications for clinical practice
Therapy of RA is still a challenge for the practising
rheumatologist, not only because none of the current
drugs or combination therapies is able to achieve long-
term full remission but also because the majority of
Figure 1. ‘Tempus tablet’ for the delayed release of prednisolone
when taken orally at bedtime (10 p.m.)
The hull of the tablet breaks apart after 4-6 hours of intestinal transit time,
and prednisolone can act immediately at the time of the lowest endogenous
steroid production. Photograph taken by UM-L.
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first, second, or even third biologic, so that novel options
are urgently needed. The recent developments in the field
of TNF inhibitors and the novel IL-6 inhibitor TOZ are
potentially an option for these needs. Moreover, the
developments in the small-molecule field may be able to
provide an applicable drug in the near future, although
sustainable efficacy and clinically acceptable side effects
still need to be proven in large-scale clinical trials. On the
other hand, the novel application form of prednisolone,
which has been manufactured according to the circadian
need for an in-time delivery of steroids in the early
morning hours, may contribute significantly to decrease
thesteroidloadforRApatients.Insummary,treatmentof
RAhasbecomemorecolourfulbutalsomorechallenging.
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